Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited logo

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited

0874.HK

HKSEHealthcareMedical - Pharmaceuticals

Latest quote

HK$14.18

−HK$0.89 · -5.91%

Aug 24, 4:08 PM HKT

0874.HK company overview

Regular session · HKT · Market data may be delayed.

Company profile

Company website

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (GBPHCL) is a comprehensive pharmaceutical enterprise focused on the research, development, production, and distribution of a wide array of medical products. These offerings span traditional Chinese patent medicines, Western pharmaceuticals, chemical raw materials and their intermediates, alongside natural and biological remedies, serving both the Chinese domestic market and international clientele. The company's operations are strategically divided into four primary segments: Great Southern TCM, Great Commerce, Great Health, and Others. Beyond its manufacturing activities, GBPHCL is actively involved in the import, export, wholesale, and retail of both Western and Chinese medicines, as well as medical equipment. The company also develops, manufactures, and sells various consumer goods including beverages, food products, health supplements, pre-packaged foods, dairy items, and diverse pharmaceutical forms such as tablets, capsules, lozenges, and injections, in addition to traditional items like tortoise herb jelly. Furthermore, GBPHCL makes strategic investments in the broader health industry, covering areas like medical services, health management, wellness initiatives, and elderly care. It also provides commercial and advertising solutions. As of December 31, 2021, the company maintained a substantial retail presence, managing 154 chain pharmacies operating under brands like Cai Zhi Lin, Jian Min, GPC Prescription Pharmacy, and Hainan Guangyao Chenfei Pharmaceutical Chain Co., Ltd, supplemented by an additional 22 independent retail stores. Established in 1997, the company originally operated as Guangzhou Pharmaceutical Company Limited before adopting its current name, Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited, in August 2013. Its headquarters are situated in Guangzhou, China.

Industry
Medical - Pharmaceuticals
Sector
Healthcare
Headquarters
CN
CEO
Hong Li
Listed since
Oct 30, 1997
Employees
27,057

Market position

Day range

Current HK$14.18

52-week range

Current HK$14.18

Open
HK$14.78
Previous close
HK$15.07
Volume
5.43M
5.4× average
Average volume
1M
Average daily volume
Market cap
35.23B HKD
Beta
0.18
Market reference 1
50-day average
HK$15.2982
-7.31% below average
200-day average
HK$17.3163
-18.11% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
31.63B CNY
P/E (TTM)
12.73×
P/B (TTM)
0.73×
P/S (TTM)
0.42×
EV / EBITDA
Earnings yield
11.53%
Free cash flow yield
-3.69%
Dividend yield
4.23%

Profitability & efficiency

Gross margin
15.48%
Operating margin
3.79%
Net margin
3.24%
Return on equity
7.89%
Return on assets
3.53%
Return on invested capital
4.81%

Financial health

Debt / equity
0.47×
Current ratio
1.57×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends21%15%8%2%Gross margin, FY2021: 19.17%Gross margin, FY2022: 18.76%Gross margin, FY2023: 18.79%Gross margin, FY2024: 16.70%Gross margin, FY2025: 16.13%Operating margin, FY2021: 6.93%Operating margin, FY2022: 7.17%Operating margin, FY2023: 6.78%Operating margin, FY2024: 4.80%Operating margin, FY2025: 4.67%Net margin, FY2021: 5.39%Net margin, FY2022: 5.60%Net margin, FY2023: 5.37%Net margin, FY2024: 3.78%Net margin, FY2025: 3.84%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 19.17%. Gross margin FY2022 18.76%. Gross margin FY2023 18.79%. Gross margin FY2024 16.70%. Gross margin FY2025 16.13%. Operating margin FY2021 6.93%. Operating margin FY2022 7.17%. Operating margin FY2023 6.78%. Operating margin FY2024 4.80%. Operating margin FY2025 4.67%. Net margin FY2021 5.39%. Net margin FY2022 5.60%. Net margin FY2023 5.37%. Net margin FY2024 3.78%. Net margin FY2025 3.84%.

Income trends

Revenue

77.66B CNY+3.55%

Operating income

3.63B CNY+0.90%

Net income

2.98B CNY+5.21%
Income trends across reported periods85.14B CNY55.21B CNY25.28B CNY−4.65B CNYRevenue, FY2021: 69.01B CNYRevenue, FY2022: 70.79B CNYRevenue, FY2023: 75.52B CNYRevenue, FY2024: 74.99B CNYRevenue, FY2025: 77.66B CNYOperating income, FY2021: 4.79B CNYOperating income, FY2022: 5.07B CNYOperating income, FY2023: 5.12B CNYOperating income, FY2024: 3.6B CNYOperating income, FY2025: 3.63B CNYNet income, FY2021: 3.72B CNYNet income, FY2022: 3.97B CNYNet income, FY2023: 4.06B CNYNet income, FY2024: 2.84B CNYNet income, FY2025: 2.98B CNYFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 69.01B CNY. Revenue FY2022 70.79B CNY. Revenue FY2023 75.52B CNY. Revenue FY2024 74.99B CNY. Revenue FY2025 77.66B CNY. Operating income FY2021 4.79B CNY. Operating income FY2022 5.07B CNY. Operating income FY2023 5.12B CNY. Operating income FY2024 3.6B CNY. Operating income FY2025 3.63B CNY. Net income FY2021 3.72B CNY. Net income FY2022 3.97B CNY. Net income FY2023 4.06B CNY. Net income FY2024 2.84B CNY. Net income FY2025 2.98B CNY.
Metric (CNY)FY2025FY2024FY2023FY2022FY2021
Revenue77.66B CNY74.99B CNY75.52B CNY70.79B CNY69.01B CNY
Cost of goods sold65.05B CNY62.47B CNY61.33B CNY57.51B CNY55.78B CNY
Gross profit12.52B CNY12.52B CNY14.19B CNY13.28B CNY13.23B CNY
Research and development591.88M CNY763.77M CNY782.14M CNY819.45M CNY874.72M CNY
Selling, general, and administrative3.14B CNY3B CNY6.71B CNY6.43B CNY6.43B CNY
Operating expenses8.89B CNY8.92B CNY9.07B CNY8.73B CNY8.85B CNY
Interest income638.25M CNY404.31M CNY462.43M CNY626.79M CNY563.87M CNY
Interest expense415.95M CNY418.15M CNY446.19M CNY434.41M CNY417.83M CNY
Depreciation and amortization931.11M CNY875.24M CNY929.44M CNY743.83M CNY676.99M CNY
Operating income3.63B CNY3.6B CNY5.12B CNY5.07B CNY4.79B CNY
Net income2.98B CNY2.84B CNY4.06B CNY3.97B CNY3.72B CNY

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
44%
4 beats, 5 misses, 0 met estimates
Average EPS surprise
-6.28%
9 comparable reports
Latest EPS result
0.22

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates1.370.80.23-0.34Q4 '24MissQ1 '25BeatQ2 '25BeatQ3 '25MissQ4 '25BeatQ1 '26MissQ2 '26No estimateQ3 '26No estimate
Q4 2024, reported Oct 25, 2024: actual 0.38, estimate 0.45, surprise -15.56%, Miss. Q1 2025, reported Mar 13, 2025: actual 0.319, estimate 0.31, surprise +3.00%, Beat. Q2 2025, reported Apr 29, 2025: actual 1.2, estimate 0.59, surprise +103.39%, Beat. Q3 2025, reported Aug 15, 2025: actual 0.471, estimate 0.493, surprise -4.58%, Miss. Q4 2025, reported Oct 28, 2025: actual 0.534, estimate 0.47, surprise +13.59%, Beat. Q1 2026, reported Mar 20, 2026: actual -0.223, estimate 0.49, surprise -145.44%, Miss. Q2 2026, reported Apr 27, 2026: actual 1.25, estimate —, surprise —, Comparison unavailable. Q3 2026, reported Aug 21, 2026: actual 0.22, estimate —, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates27.51B23.64B19.76B15.89BQ4 '24BeatQ1 '25MissQ2 '25No estimateQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26No estimateQ3 '26No estimate
Q4 2024, reported Oct 25, 2024: actual 19.94B HKD, estimate 18.61B HKD, surprise +7.15%, Beat. Q1 2025, reported Mar 13, 2025: actual 16.95B HKD, estimate 18.59B HKD, surprise -8.83%, Miss. Q2 2025, reported Apr 29, 2025: actual 23.98B HKD, estimate —, surprise —, Comparison unavailable. Q3 2025, reported Aug 15, 2025: actual 21.22B HKD, estimate 21.2B HKD, surprise +0.05%, Beat. Q4 2025, reported Oct 28, 2025: actual 21.62B HKD, estimate 21.6B HKD, surprise +0.07%, Beat. Q1 2026, reported Mar 20, 2026: actual 17.86B HKD, estimate 17.59B HKD, surprise +1.53%, Beat. Q2 2026, reported Apr 27, 2026: actual 26.45B HKD, estimate —, surprise —, Comparison unavailable. Q3 2026, reported Aug 21, 2026: actual 21.64B HKD, estimate —, surprise —, Comparison unavailable.

Corporate actions

Annual dividends per share

Cash distributions grouped by calendar year; partial years are marked.

HK$0.8761

2025 complete year+33.8% since 2021

2026 partial: HK$0.5162

* Partial calendar year in the available dividend history.

Corporate action history

Dividend

Ex-dividend Jun 12, 2026

HK$0.5162

Semi-Annual

Record Jun 15, 2026 · Payment Jul 17, 2026

Dividend

Ex-dividend Aug 29, 2025

HK$0.4399

Semi-Annual

Record Sep 1, 2025 · Payment Sep 26, 2025

Dividend

Ex-dividend Jun 16, 2025

HK$0.4362

Semi-Annual

Record Jun 17, 2025 · Payment Jul 18, 2025

Dividend

Ex-dividend Oct 15, 2024

HK$0.4422

Semi-Annual

Record Oct 16, 2024 · Payment Nov 15, 2024

Dividend

Ex-dividend Jun 13, 2024

HK$0.8227

Semi-Annual

Record Jun 14, 2024 · Payment Jul 18, 2024

Dividend

Ex-dividend Jun 14, 2023

HK$0.8126

Annual

Record Jun 15, 2023 · Payment Jul 17, 2023

0874.HK peers

Continue in GoAI

Research 0874.HK

research.disclaimer